On-treatment predictors during antiviral therapy of HCV are useful because they allow discontinuation of an unnecessary treatment in non-responders. Our aim was to evaluate the usefulness of plasma and erythrocyte ribavirin levels in predicting sustained virological response (SVR) in HCV genotype 1 patients undergoing antiviral treatment.
Methods
A total of 40 HCV genotype 1 patients treated with pegylated interferon-α2a 180 μg weekly plus ribavirin 1,000 or 1,200 mg daily (according to body weight) were included in the study. Plasma and erythrocyte ribavirin levels were evaluated in all patients at week 12 by HPLC. At week 24, ribavirin levels were reassessed in those achieving early virological response (EVR).
Results
A total of 27 patients achieved EVR, whereas 17 achieved SVR. There was no difference among EVR and non-EVR patients in terms of plasma and erythrocyte ribavirin concentrations at week 12. At week 24, EVR patients obtaining SVR exhibited higher mean ±sd levels of ribavirin in plasma and lower levels in erythrocytes compared with non-SVR patients (in plasma 12.8 ±10 versus 5.8 ±4 μM [P<0.02] and in erythrocytes 1,053 ±504 versus 1,613 ±589 μM [P<0.03]). When the plasma ribavirin/erythrocyte ribavirin x100 ratio was compared, the difference was enhanced (1.5 ±1.3 versus 0.4 ±0.3 μM; P<0.01). Receiver operating characteristic curve analysis identified a cutoff for plasma ribavirin/erythrocyte ribavirin x100 ratio in predicting SVR of 0.71 with a negative predictive value of 0.8 and a positive predictive value of 0.9, whereas those related to EVR were 1 and 0.6, respectively.
Conclusions
Plasma ribavirin/erythrocyte ribavirin x100 ratio at week 24 seems to be a good indicator of SVR in HCV genotype 1 patients achieving EVR.
References
1.
MühlbergerN., SchwarzerR., LettmeierB., SroczynskiG., ZeuzemS., SiebertU.HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality.BMC Public Health2009; 9: 34.
2.
BrunoS., StroffoliniT., ColomboM.Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study.Hepatology2007; 45: 579–587.
3.
KauA., VermehrenJ., SarrazinC.Treatment predictors of a sustained virologic response in hepatitis B and C.J Hepatol2008; 49: 634–651.
4.
HadziyannisS.J., SetteH.Jr.MorganT.R.Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose.Ann Intern Med2004; 140: 346–355.
5.
MannsM.P., McHutchisonJ.G., GordonS.C.Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.Lancet2001; 358: 958–965.
6.
FriedM.W., ShiffmanM.L., ReddyK.R.Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.N Engl J Med2002; 347: 975–982.
7.
DavisG.L.Monitoring of viral levels during therapy of hepatitis C.Hepatology2002; 36 Suppl 1: S145–S151.
8.
DavisG.L., WongJ.B., McHutchisonJ.G., MannsM.P., HarveyJ., AlbrechtJ.Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C.Hepatology2003; 38: 645–652.
9.
YuJ.W., WangG.Q., SunL.J., LiX.G., LiS.C.Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin.J Gastroenterol Hepatol2007; 22: 832–836.
10.
JensenD.M., MorganT.R., MarcellinP.Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy.Hepatology2006; 43: 954–960.
11.
MangiaA., MinervaN., BaccaD.Individualized treatment duration for hepatitis C genotype 1 patients: a randomized controlled trial.Hepatology2008; 47: 43–50.
12.
SalmerónJ., CasadoJ., RuedaP.M.Quasispecies as predictive factor of rapid, early and sustained virological responses in chronic hepatitis C, genotype 1, treated with peginterferon-ribavirin.J Clin Virol2008; 41: 264–269.
13.
McHutchisonJ.G., MannsM., PatelK.Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C.Gastroenterology2002; 123: 1061–1069.
14.
ShiffmanM.L., GhanyM.G., MorganT.R.Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C.Gastroenterology2007; 132: 103–112.
15.
BainV.G., LeeS.S., PeltekianK.Clinical trial: exposure to ribavirin predicts EVR and SVR in patients with HCV genotype 1 infection treated with peginterferon alpha-2a plus ribavirin.Aliment Pharmacol Ther2008; 28: 43–50.
16.
MartinP., JensenD.M.Ribavirin in the treatment of chronic hepatitis C.J Gastroenterol Hepatol2008; 23: 844–855.
17.
Loustaud-RattiV., AlainS., RousseauA.Ribavirin exposure after the first dose is predictive of sustained virological response in chronic hepatitis C.Hepatology2008; 47: 1453–1461.
18.
LindahlK., SchvarczR., BruchfeldA., StåhleL.Evidence that plasma concentration rather than dose per kilogram body weight predicts ribavirin-induced anaemia.J Viral Hepat2004; 11: 84–87.
19.
InoueY., HommaM., MatsuzakiY.Erythrocyte ribavirin concentration for assessing hemoglobin reduction in interferon and ribavirin combination therapy.Hepatol Res2006; 34: 23–27.
20.
WadeJ.R., SnoeckE., DuffF., LambM., JorgaK.Pharmacokinetics of ribavirin in patients with hepatitis C virus.Br J Clin Pharmacol2006; 62: 710–714.
21.
HommaM., JayewardeneA.L., GambertoglioJ., AweekaF.High-performance liquid chromatographic determination of ribavirin in whole blood to assess disposition in erythrocytes.Antimicrob Agents Chemother1999; 43: 2716–2719.
22.
InoueY., HommaM., MatsuzakiY.Liquid chromatography assay for routine monitoring of cellular ribavirin levels in blood.Antimicrob Agents Chemother2004; 48: 3813–3816.
23.
GhanyM.G., StraderD.B., ThomasD.L., SeeffL.B., American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update.Hepatology2009; 49: 1335–1374.
24.
CarlssonT., ReichardO., NorkransG.Hepatitis C virus RNA kinetics during the initial 12 weeks treatment with pegylated interferon-alpha 2a and ribavirin according to virological response.J Viral Hepat2005; 12: 473–480.
25.
FerenciP., FriedM.W., ShiffmanM.L.Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ ribavirin.J Hepatol2005; 43: 425–433.
26.
Di BisceglieA.M., ShindoM., FongT.L.A pilot study of ribavirin therapy for chronic hepatitis C.Hepatology1992; 16: 649–654.
27.
DusheikoG., MainJ., ThomasH.Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study.J Hepatol1996; 25: 591–598.
28.
PoynardT., MarcellinP., LeeS.S.Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus.Lancet1998; 352: 1426–1432.
29.
GlueP., Rouzier-PanisR., RaffanelC.A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C.Hepatology2000; 32: 647–653.
30.
BronowickiJ.P., OuzanD., AsselahT.Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin.Gastroenterology2006; 131: 1040–1048.
31.
RamosB., NúñezM., RendónA.Critical role of ribavirin for the achievement of early virological response to HCV therapy in HCV/HIV-coinfected patients.J Viral Hepat2007; 14: 387–391.
32.
DahariH., MarkatouM., ZeremskiM.Early ribavirin pharmacokinetics, HCV RNA and alanine aminotransferase kinetics in HIV/HCV co-infected patients during treatment with pegylated interferon and ribavirin.J Hepatol2007; 47: 23–30.
33.
LarratS., Stanke-LabesqueF., PlagesA., ZarskiJ.P., BessardG., SouvignetC.Ribavirin quantification in combination treatment of chronic hepatitis C.Antimicrob Agents Chemother2003; 47: 124–129.
34.
AraseY., IkedaK., TsubotaA.Significance of serum ribavirin concentration in combination therapy of interferon and ribavirin for chronic hepatitis C.Intervirology2005; 48: 138–144.
35.
DonnererJ., GrahovacM., StelzlE.Ribavirin levels and haemoglobin decline in early virological responders and non-responders to hepatitis C virus combination therapy.Pharmacology2006; 76: 136–140.
36.
NicotF., Legrand-AbravanelF., LafontT.Serum concentrations of ribavirin and pegylated interferon and viral responses in patients infected with HIV and HCV.J Med Virol2008; 80: 1523–1529.
37.
Aguilar MaruccoD., Gonzalez de RequenaD., BonoraS.The use of trough ribavirin concentration to predict sustained virological response and haematological toxicity in HIV/HCV-co-infected patients treated with ribavirin and pegylated interferon.J Antimicrob Chemother2008; 61: 919–924.
38.
MaynardM., PradatP., GagnieuM.C., SouvignetC., TrepoC.Prediction of sustained virological response by ribavirin plasma concentration at week 4 of therapy in hepatitis C virus genotype 1 patients.Antivir Ther2008; 13: 607–611.
39.
PageT., ConnorJ.D.The metabolism of ribavirin in erythrocytes and nucleated cells.Int J Biochem1990; 22: 379–383.
40.
SaitoH., TadaS., EbinumaH.Role of erythrocytes as a reservoir for ribavirin and relationship with adverse reactions in the early phase of interferon combination therapy for chronic hepatitis C virus infections.J Clin Microbiol2006; 44: 3562–3568.
41.
De FranceschiL., FattovichG., TurriniF.Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage.Hepatology2000; 31: 997–1004.
42.
TiffertT., DawN., EtzionZ., BookchinR.M., LewV.L.Age decline in the activity of the Ca2+-sensitive K+ channel of human red blood cells.J Gen Physiol2007; 129: 429–436.
